RAPID-PsA: A 24-week trial in patients with active PsA

RAPID-PsA study design1,10

Graph representing RAPID-PsA study design

The RAPID-PsA trial was a phase 3 trial conducted in patients with PsA to evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks. In this study, 409 patients were randomized (1:1:1) to CIMZIA 200 mg q2w (n=138), CZP 400 mg q4w (n=135), or placebo (n=136). All patients received a loading dose with CIMZIA 400 mg or placebo at weeks 0, 2, and 4. Eligible patients had adult onset active PsA ≥6 months’ duration as defined by the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria, active psoriatic lesions or a documented history of psoriasis, ≥3 tender and ≥3 swollen joints, erythrocyte sedimentation rate ≥28 mm/hr (Westergren) and/or C-reactive protein greater than the upper limit of normal, and failed ≥1 DMARD (nonbiologic or biologic). Patients were stratified by study site and prior TNF inhibitor-alpha (TNF-α) exposure. Primary nonresponders were excluded. Patients were evaluated for signs and symptoms and structural damage using the ACR20 response at week 12 and the modified total Sharp score (mTSS) at week 24.1,10